Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
December 31, 2006
Study Completion Date
February 28, 2007
Conditions
Muscle Spasticity
Interventions
DRUG
Tizanidine (sublingual or oral)
Trial Locations (1)
Unknown
Tel Aviv Sourasky Medical Center- Neurology Department, Tel Aviv
All Listed Sponsors
lead
Teva GTC
INDUSTRY
NCT00358293 - Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity | Biotech Hunter | Biotech Hunter